Rou-Min Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rou-Min Wang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Zhi-Ying Wu
Department of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine and Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou, China
7 shared publications - Yi Dong
Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
3 shared publications - Guo-Min Yang
Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications Hao Yu
Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications- Ni Wang
Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications Wan-Qing Xu
Departments of Neurology and Medical Genetics, Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications
Latest Publications
- 24 August 2026
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (17) , 4989-4996
A near-infrared AND logic fluorescent probe that simultaneously responds to Cu 2+ and hypochlorous acid for the imaging of Wilson's disease
A near-infrared AND logic fluorescent probe activated by dual inputs of Cu 2+ and HOCl for liver-targeted specific imaging of Wilson's disease.
- 24 August 2026
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (17) , 4989-4996
A near-infrared AND logic fluorescent probe that simultaneously responds to Cu 2+ and hypochlorous acid for the imaging of Wilson's disease
A near-infrared AND logic fluorescent probe activated by dual inputs of Cu 2+ and HOCl for liver-targeted specific imaging of Wilson's disease.
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (19) , e48686
Occult cirrhosis presenting as progressive tremor: acquired hepatocerebral degeneration induced by traditional Chinese medicine and natural health products, aggravated by manganese supplements: A case report
Rationale: Acquired hepatocerebral degeneration (AHD) is a rare neurological complication of chronic liver disease or portosystemic shunting, typically characterized by extrapyramidal symptoms and manganese accumulation in the basal ganglia. Its diagnosis is particularly challenging in patients with occult cirrhosis and complex exposure histories, especially when traditional Chinese medicines (TCM) and natural health products (NHPs) contribute to hepatotoxicity. Patient concerns: A 66-year-old woman presented with a 2-year history of progressive postural and intention tremor, with marked worsening over the preceding 2 months, interfering with daily activities. Diagnoses: Laboratory tests indicated hepatic dysfunction and cirrhosis, while neuroimaging revealed bilateral T1 hyperintensity in the basal ganglia. Extensive evaluation excluded viral hepatitis, alcohol-related liver disease, autoimmune liver disease, Wilson disease, and occupational toxic exposure. Whole-blood manganese was markedly elevated. Detailed history-taking revealed long-term use of hepatotoxic TCM (notably Psoralea corylifolia ) and manganese-containing supplements. A diagnosis of manganese-related AHD secondary to cirrhosis, likely induced by chronic TCM/NHPs exposure, was established. Interventions: Management included discontinuation of hepatotoxic agents and manganese-rich supplements, implementation of a low-manganese diet, hepatoprotective therapy, ammonia-lowering treatment, symptomatic control of tremor (clonazepam and trihexyphenidyl), and chelation therapy with dimercaptosuccinic acid. Outcomes: At follow-up, liver function and ammonia levels improved, whole-blood manganese levels decreased but remained elevated, and tremor severity was significantly reduced with corresponding functional improvement. Lessons: This case highlights that AHD may arise in the setting of occult cirrhosis related to long-term TCM/NHPs use, with additional manganese exposure acting as a precipitating factor. Clinicians should routinely screen for liver dysfunction in patients with unexplained extrapyramidal symptoms, incorporate manganese testing and basal ganglia magnetic resonance imaging into diagnostic evaluation, and systematically inquire about TCM/NHPs use. Multidisciplinary management is crucial, particularly in regions with widespread use of TCM and NHPs.
- 8 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (19) , e48686
Open AccessOccult cirrhosis presenting as progressive tremor: acquired hepatocerebral degeneration induced by traditional Chinese medicine and natural health products, aggravated by manganese supplements: A case report
Rationale: Acquired hepatocerebral degeneration (AHD) is a rare neurological complication of chronic liver disease or portosystemic shunting, typically characterized by extrapyramidal symptoms and manganese accumulation in the basal ganglia. Its diagnosis is particularly challenging in patients with occult cirrhosis and complex exposure histories, especially when traditional Chinese medicines (TCM) and natural health products (NHPs) contribute to hepatotoxicity. Patient concerns: A 66-year-old woman presented with a 2-year history of progressive postural and intention tremor, with marked worsening over the preceding 2 months, interfering with daily activities. Diagnoses: Laboratory tests indicated hepatic dysfunction and cirrhosis, while neuroimaging revealed bilateral T1 hyperintensity in the basal ganglia. Extensive evaluation excluded viral hepatitis, alcohol-related liver disease, autoimmune liver disease, Wilson disease, and occupational toxic exposure. Whole-blood manganese was markedly elevated. Detailed history-taking revealed long-term use of hepatotoxic TCM (notably Psoralea corylifolia ) and manganese-containing supplements. A diagnosis of manganese-related AHD secondary to cirrhosis, likely induced by chronic TCM/NHPs exposure, was established. Interventions: Management included discontinuation of hepatotoxic agents and manganese-rich supplements, implementation of a low-manganese diet, hepatoprotective therapy, ammonia-lowering treatment, symptomatic control of tremor (clonazepam and trihexyphenidyl), and chelation therapy with dimercaptosuccinic acid. Outcomes: At follow-up, liver function and ammonia levels improved, whole-blood manganese levels decreased but remained elevated, and tremor severity was significantly reduced with corresponding functional improvement. Lessons: This case highlights that AHD may arise in the setting of occult cirrhosis related to long-term TCM/NHPs use, with additional manganese exposure acting as a precipitating factor. Clinicians should routinely screen for liver dysfunction in patients with unexplained extrapyramidal symptoms, incorporate manganese testing and basal ganglia magnetic resonance imaging into diagnostic evaluation, and systematically inquire about TCM/NHPs use. Multidisciplinary management is crucial, particularly in regions with widespread use of TCM and NHPs.
- 4 November 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (1) , 57-67
Pathogenicity of Intronic and Synonymous Variants of ATP7B in Wilson Disease
- 4 November 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (1) , 57-67
Pathogenicity of Intronic and Synonymous Variants of ATP7B in Wilson Disease
- 4 August 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 36 (8) , 2273-2281
A novel ceruloplasmin mutation identified in a Chinese patient and clinical spectrum of aceruloplasminemia patients
Aceruloplasminemia (ACP) is a rare disorder of iron overload resulting from ceruloplasmin (CP) variants. Because of its rarity and heterogeneity, the diagnosis of ACP is often missed or misdiagnosed. Here, we aim to present a clinical spectrum of ACP and raise more attention to the early diagnosis. Whole exome sequencing (WES) was performed in a Chinese female patient suspected with ACP and her clinical data were collected in detail. The PubMed databases was searched for published ACP patients within the last decade, and we present a systematic review of their clinical features with data extracted from these researches. A novel pathogenic variant (c.2689delC) and a known pathogenic variant (c.606dupA) within ceruloplasmin gene were identified in our patient and confirmed the diagnosis of ACP. Then we reviewed 51 ACP patients including the case we reported here. A possible timeline of symptoms was discovered, anemia appears first (29.7 years old on average), followed by diabetes (37.3 years old) and finally neurological symptoms (50.7 years old). The delay in diagnosis was significantly shortened in patients without neurological symptoms. Biochemical triad including anemia, low to undetectable serum ceruloplasmin, low serum iron and/or hyperferritinemia, showed better sensitivity in diagnosis than clinical triad including diabetes, neurological symptoms, and retinal degeneration. Due to the variable symptom spectrum, patients with ACP often visit different departments, which can lead to misdiagnosis. Clinical attention needs to be paid to symptoms and tests that have a warning effect. Prompt diagnosis in the early stage of the disease can be beneficial.
- 4 August 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 36 (8) , 2273-2281
A novel ceruloplasmin mutation identified in a Chinese patient and clinical spectrum of aceruloplasminemia patients
Aceruloplasminemia (ACP) is a rare disorder of iron overload resulting from ceruloplasmin (CP) variants. Because of its rarity and heterogeneity, the diagnosis of ACP is often missed or misdiagnosed. Here, we aim to present a clinical spectrum of ACP and raise more attention to the early diagnosis. Whole exome sequencing (WES) was performed in a Chinese female patient suspected with ACP and her clinical data were collected in detail. The PubMed databases was searched for published ACP patients within the last decade, and we present a systematic review of their clinical features with data extracted from these researches. A novel pathogenic variant (c.2689delC) and a known pathogenic variant (c.606dupA) within ceruloplasmin gene were identified in our patient and confirmed the diagnosis of ACP. Then we reviewed 51 ACP patients including the case we reported here. A possible timeline of symptoms was discovered, anemia appears first (29.7 years old on average), followed by diabetes (37.3 years old) and finally neurological symptoms (50.7 years old). The delay in diagnosis was significantly shortened in patients without neurological symptoms. Biochemical triad including anemia, low to undetectable serum ceruloplasmin, low serum iron and/or hyperferritinemia, showed better sensitivity in diagnosis than clinical triad including diabetes, neurological symptoms, and retinal degeneration. Due to the variable symptom spectrum, patients with ACP often visit different departments, which can lead to misdiagnosis. Clinical attention needs to be paid to symptoms and tests that have a warning effect. Prompt diagnosis in the early stage of the disease can be beneficial.
- 1 March 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 19 (3) , 590-596
Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson’s Disease
- 1 March 2021
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 19 (3) , 590-596
Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson’s Disease
- Open Access
Prevalent Pathogenic Variants of ATP7B in Chinese Patients with Wilson’s Disease: Geographical Distribution and Founder Effect
Wilson’s disease (WD) is an autosomal recessive disorder caused by ATP7B pathogenic variants. This study aimed to show the geographical distribution and haplotype spectrum of three prevalent pathogenic variants (p.R778L, p.P992L, p.T935M) in mainland Chinese population and clarify whether the founder effect may account for their origins. We firstly summarized the frequency and geographical distribution of p.R778L, p.P992L and p.T935M in 715 WD patients. Then, to construct haplotypes associated with the three variants, Sanger sequencing and microsatellite typing at three dinucleotide-repeat markers (D13S314, D13S301, D13S316) flanking the ATP7B gene were performed in 102 WD families. An obvious regional-specific distribution feature was found in p.T935M. Linkage disequilibrium at the three markers was shown in all the three variants and we found the common haplotypes specific for p.R778L, p.P992L and p.T935M respectively, represented successively by 10-7-7, 10-9-5 and 12-4-8, which all exhibited great significance vs. the control chromosomes (p < 0.01). Meanwhile, haplotypes for the three variants differed from the studies in other regions to some extent. The common haplotypes we found indicate that three prevalent pathogenic variants emerge due to the founder effect. Furthermore, the study contributes to expand our knowledge of the genetic diversity of WD from a cross-regional perspective.
Open AccessPrevalent Pathogenic Variants of ATP7B in Chinese Patients with Wilson’s Disease: Geographical Distribution and Founder Effect
Wilson’s disease (WD) is an autosomal recessive disorder caused by ATP7B pathogenic variants. This study aimed to show the geographical distribution and haplotype spectrum of three prevalent pathogenic variants (p.R778L, p.P992L, p.T935M) in mainland Chinese population and clarify whether the founder effect may account for their origins. We firstly summarized the frequency and geographical distribution of p.R778L, p.P992L and p.T935M in 715 WD patients. Then, to construct haplotypes associated with the three variants, Sanger sequencing and microsatellite typing at three dinucleotide-repeat markers (D13S314, D13S301, D13S316) flanking the ATP7B gene were performed in 102 WD families. An obvious regional-specific distribution feature was found in p.T935M. Linkage disequilibrium at the three markers was shown in all the three variants and we found the common haplotypes specific for p.R778L, p.P992L and p.T935M respectively, represented successively by 10-7-7, 10-9-5 and 12-4-8, which all exhibited great significance vs. the control chromosomes (p < 0.01). Meanwhile, haplotypes for the three variants differed from the studies in other regions to some extent. The common haplotypes we found indicate that three prevalent pathogenic variants emerge due to the founder effect. Furthermore, the study contributes to expand our knowledge of the genetic diversity of WD from a cross-regional perspective.
- Open Access
- 13 April 2020
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 26 (8) , 842-850
Clinical features and outcome of Wilson's disease with generalized epilepsy in Chinese patients
Objective Generalized epilepsy is rarely reported in patients with Wilson disease (WD) and lacks experience in clinical practice. We aim to provide better experience for the diagnosis and treatment for WD patients with epilepsy in the future. Methods A retrospective study was performed in 13 Chinese WD patients with generalized epilepsy. Each patient was diagnosed with WD by clinical evaluation and genetic screening. Patients were given small doses of antiepileptic drugs (AEDs), followed by copper‐chelation therapy when the seizures stabilized. Clinical manifestations, brain imaging changes, and treatment and outcome after a long‐term follow‐up were analyzed. Results Four out of 13 (30.8%) patients stopped taking copper‐chelation drugs for more than 1 year before they were admitted for epilepsy. The incidence of epilepsy of WD patients in our cohort is 1.43% (13/910), lower than those (4.5%‐5.9%) in other populations. After the attack of epilepsy, frontal lobes were the most common abnormalities (13/13, 100%) in patients, followed by brain stem (8/13, 61.5%) and thalamus (7/13, 53.8%). After a long‐term follow‐up, brain imaging and clinical manifestations of 8 (8/9, 88.9%) WD patients were significantly improved. Conclusions We firstly described WD patients with generalized epilepsy in the Chinese population. WD patients with aggravation of neuropsychiatric symptoms are prone to occur epilepsy; thus, brain MRI should be performed regularly in those patients. Cortical abnormality in brain MRI is a warning sign of epilepsy. Irregular use of copper‐chelation drugs and excessive copper deposition in the brain may be the cause of seizures. Long‐term standardized treatment for WD can effectively prevent the extensive brain damage and reduce the incidence of epilepsy in WD patients.
- 13 April 2020
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 26 (8) , 842-850
Open AccessClinical features and outcome of Wilson's disease with generalized epilepsy in Chinese patients
Objective Generalized epilepsy is rarely reported in patients with Wilson disease (WD) and lacks experience in clinical practice. We aim to provide better experience for the diagnosis and treatment for WD patients with epilepsy in the future. Methods A retrospective study was performed in 13 Chinese WD patients with generalized epilepsy. Each patient was diagnosed with WD by clinical evaluation and genetic screening. Patients were given small doses of antiepileptic drugs (AEDs), followed by copper‐chelation therapy when the seizures stabilized. Clinical manifestations, brain imaging changes, and treatment and outcome after a long‐term follow‐up were analyzed. Results Four out of 13 (30.8%) patients stopped taking copper‐chelation drugs for more than 1 year before they were admitted for epilepsy. The incidence of epilepsy of WD patients in our cohort is 1.43% (13/910), lower than those (4.5%‐5.9%) in other populations. After the attack of epilepsy, frontal lobes were the most common abnormalities (13/13, 100%) in patients, followed by brain stem (8/13, 61.5%) and thalamus (7/13, 53.8%). After a long‐term follow‐up, brain imaging and clinical manifestations of 8 (8/9, 88.9%) WD patients were significantly improved. Conclusions We firstly described WD patients with generalized epilepsy in the Chinese population. WD patients with aggravation of neuropsychiatric symptoms are prone to occur epilepsy; thus, brain MRI should be performed regularly in those patients. Cortical abnormality in brain MRI is a warning sign of epilepsy. Irregular use of copper‐chelation drugs and excessive copper deposition in the brain may be the cause of seizures. Long‐term standardized treatment for WD can effectively prevent the extensive brain damage and reduce the incidence of epilepsy in WD patients.
- Open Access
- 26 June 2019
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 8 (1) , 1-13
Clinical features and genetic spectrum in Chinese patients with recessive hereditary spastic paraplegia
Although many causative genes of hereditary spastic paraplegia (HSP) have been uncovered in recent years, there are still approximately 50% of HSP patients without genetically diagnosis, especially in autosomal recessive (AR) HSP patients. Rare studies have been performed to determine the genetic spectrum and clinical profiles of recessive HSP patients in the Chinese population. In this study, we investigated 24 Chinese index AR/sporadic patients by targeted next-generation sequencing (NGS), Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA). Further functional studies were performed to identify pathogenicity of those uncertain significance variants. We identified 11 mutations in HSP related genes including 7 novel mutations, including two (p.V1979_L1980delinsX, p.F2343 fs) in SPG11, two (p.T55 M, p.S308 T) in AP5Z1, one (p.S242 N) in ALDH18A1, one (p.D597fs) in GBA2, and one (p.Q486X) in ATP13A2 in 8 index patients and their family members. Mutations in ALDH18A1, AP5Z1, CAPN1 and ATP13A2 genes were firstly reported in the Chinese population. Furthermore, the clinical phenotypes of the patients carrying mutations were described in detail. The mutation (p.S242 N) in ALDH18A1 decreased enzyme activity of P5CS and mutations (p.T55 M, p.S308 T) in AP5Z1 induced lysosomal dysfunction. Our results expanded the genetic spectrum and clinical profiles of AR-HSP patients and further demonstrated the efficiency and reliability of targeted NGS diagnosing suspected HSP patients.
- 26 June 2019
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 8 (1) , 1-13
Open AccessClinical features and genetic spectrum in Chinese patients with recessive hereditary spastic paraplegia
Although many causative genes of hereditary spastic paraplegia (HSP) have been uncovered in recent years, there are still approximately 50% of HSP patients without genetically diagnosis, especially in autosomal recessive (AR) HSP patients. Rare studies have been performed to determine the genetic spectrum and clinical profiles of recessive HSP patients in the Chinese population. In this study, we investigated 24 Chinese index AR/sporadic patients by targeted next-generation sequencing (NGS), Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA). Further functional studies were performed to identify pathogenicity of those uncertain significance variants. We identified 11 mutations in HSP related genes including 7 novel mutations, including two (p.V1979_L1980delinsX, p.F2343 fs) in SPG11, two (p.T55 M, p.S308 T) in AP5Z1, one (p.S242 N) in ALDH18A1, one (p.D597fs) in GBA2, and one (p.Q486X) in ATP13A2 in 8 index patients and their family members. Mutations in ALDH18A1, AP5Z1, CAPN1 and ATP13A2 genes were firstly reported in the Chinese population. Furthermore, the clinical phenotypes of the patients carrying mutations were described in detail. The mutation (p.S242 N) in ALDH18A1 decreased enzyme activity of P5CS and mutations (p.T55 M, p.S308 T) in AP5Z1 induced lysosomal dysfunction. Our results expanded the genetic spectrum and clinical profiles of AR-HSP patients and further demonstrated the efficiency and reliability of targeted NGS diagnosing suspected HSP patients.